Last reviewed · How we verify
Long-acting nicotine replacement therapy
At a glance
| Generic name | Long-acting nicotine replacement therapy |
|---|---|
| Also known as | Transdermal nicotine |
| Sponsor | Joseph Valentino, MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (PHASE2)
- Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Smoking (Trial 1) (PHASE2, PHASE3)
- A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV (PHASE4)
- The Canadian HIV Quit Smoking Trial: Tackling the Co-morbidities of Depression and Cardiovascular Disease in HIV+ Smokers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: